Choosing An Io/Tki Doublet For Rcc Patients: Efficacy Data, Dosing, And More

Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and More

GU Oncology Now

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

Comparing IO/TKI and TKI monotherapy for kidney cancer

Frontline RCC Treatment Selection: IO/IO Versus IO/TKI

GU Oncology Now

Patient Selection for IO/IO Versus IO/TKI in the Frontline Setting

GU Oncology Now

RCC Doublet Considerations: Immune-Mediated Toxicity, Duration of Treatment, and More

GU Oncology Now

Balancing Risks and Rewards in RCC: IO Combinations for Different Patient Profiles

GU Oncology Now

First-line treatment decision making for patients with RCC

NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Patient Scenarios and Treatment Considerations in the Adjuvant RCC Setting

GU Oncology Now

IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment

GU Oncology Now

TKI/IO Comparison: Lenvatinib/Pembrolizumab vs Cabozantinib/Nivolumab vs Axitinib/Pembrolizumab

GU Oncology Now

IO-IO and IO-TKI treatments could improve 5-year survival rate for aRCC

Dosing and Combinations of Sunitinib vis-à-vis Alternative Therapies for RCC

The Latest Data on IO/TKI Versus IO/IO in Frontline RCC

GU Oncology Now

mRCC: Identifying and Managing AEs in TKIs and IO Therapy

IO-IO vs. IO-VEGF inhibitor therapy for mRCC

mRCC: When is TKI/I-O Combination Therapy Appropriate?

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC